AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
January 03, 2019 04:00 ET
|
AC Immune SA
Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today...
AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership
December 19, 2018 06:30 ET
|
AC Immune SA
AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can...
AC Immune and Lilly Announce License and Collaboration Agreement
December 12, 2018 06:30 ET
|
AC Immune SA
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial...
In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away
December 07, 2018 16:15 ET
|
AC Immune SA
Lausanne, Switzerland, December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs, passed away following a period of illness. "It is with...
AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease
November 15, 2018 04:00 ET
|
AC Immune SA
Grant supports next step in development of potentially first alpha-synuclein PET tracer for Parkinson's diseaseStart of first-in-human study of current lead is scheduled for Q1 2019Follow-up...
AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
November 13, 2018 04:00 ET
|
AC Immune SA
Announced important clinical milestones for ACI-24 vaccine in Alzheimer's disease and Down Syndrome Company record high, period end cash position of approximately CHF 200 million that is...
AC Immune to Present at the Jefferies 2018 London Healthcare Conference
November 12, 2018 04:00 ET
|
AC Immune SA
Lausanne, Switzerland, November 12, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases
November 09, 2018 04:00 ET
|
AC Immune SA
Increasing evidence points to Abeta oligomers as the toxic species in AD, and likely linked to Tau pathology and neuroinflammation. Immunotherapies and small molecule anti-Tau therapeutics hold...
AC Immune to Present at 2018 Society for Neurosciences Meeting
November 01, 2018 06:00 ET
|
AC Immune SA
Update on Therapeutic and Diagnostic Programs Targeting TDP-43 Lausanne, Switzerland, November 1, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company...
AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases
November 01, 2018 05:00 ET
|
AC Immune SA
Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseasesMeeting scheduled for November 5, 2018, from 12:00pm...